| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 3, June 24（Tue.）
Room P (Maesato East, Foyer, Ocean Wing)
- 3P-PM-19
Fundamental study for simultaneous analysis of capecitabine and its metabolites using liquid chromatography/tandem mass spectrometry
(1Grad. Sch. Pharm. Sci., Tohoku Univ., 2Dept. Pharm. Sci., Tohoku Univ. Hosp.)
oMinami Yamauchi1, Masamitsu Maekawa1,2, Nariyasu Mano1,2
Capecitabine is the prodrug of fluoropyrimidine anticancer drug 5-fluorouracil (5-FU). Although the safety profile of capecitabine is superior to that of 5-FU, the incidence of hand-foot syndrome (HFS) is higher than that of 5-FU. The mechanism of HFS is not fully elucidated, the involvement of capecitabine metabolites in the pathogenesis of HFS has been suggested. Thus, comprehensive understanding of capecitabine pharmacokinetics in HFS patients is important. However, capecitabine and its metabolites have remarkable differences in polarity, multiple analyses are required to measure all these compounds until now. Here, we aimed to establish the LC/MS/MS method to quantify capecitabine and its metabolites simultaneously.
After optimizing the SRM transitions and ionization parameters, analytical column and mobile phase conditions are investigated to achieve the separation of all compounds. PC HILIC column held all compounds at the proportion of acetonitrile of 95% and gradient elution was succeeded. The linearity of all calibration curves was met R2 > 0.99. Out of 8 compounds, the matrix factors of 5 compounds were in ± 15% when normalized by IS, but the others were out of the range. We will continue to make improvements and develop the method that can measure all target compounds simultaneously.